BMO Analysts Express Cautious Optimism on Novo Nordisk’s 2027 Outlook

After meeting Novo Nordisk’s investor relations team in Toronto, BMO analysts described the 2027 commercial outlook as cautiously optimistic, while noting potential headwinds. The company has not provided formal guidance; guidance is expected with fourth-quarter 2026 results in early February 2027.